Company Overview of Sopherion Therapeutics, LLC
Sopherion Therapeutics, LLC operates as a biopharmaceutical company. The company, through its subsidiary, Sopherion Therapeutics Canada, develops and commercializes anti-cancer therapies for patients suffering with advanced cancer in North America. Its lead product candidate, Myocet, is in Phase III development stage for the first-line treatment of metastatic breast cancer. Sopherion Therapeutics, LLC was founded in 2001 and is based in Princeton, New Jersey with additional offices in Cheshire, Connecticut and Estero, Florida; and an operating subsidiary in Toronto, Canada.
104 Carnegie Center
Princeton, NJ 08540
Founded in 2001
Key Executives for Sopherion Therapeutics, LLC
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Sopherion Therapeutics, LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.